{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:09:01Z","timestamp":1791605341348,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00198-025-07808-3","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:12:29Z","timestamp":1773997949000},"page":"867-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"given":"India","family":"Richardson-Thornton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Streeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti L.","family":"Gild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"7808_CR1","doi-asserted-by":"publisher","DOI":"10.7326\/aitc201708010","volume":"167","author":"KE Ensrud","year":"2017","unstructured":"Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Intern Med 167:ITC17. https:\/\/doi.org\/10.7326\/aitc201708010","journal-title":"Ann Intern Med"},{"key":"7808_CR2","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018. https:\/\/doi.org\/10.1016\/S0140-6736(06)68891-0","journal-title":"Lancet"},{"key":"7808_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"7808_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/nejmoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/nejmoa1607948","journal-title":"N Engl J Med"},{"key":"7808_CR5","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(17)31613-6","journal-title":"Lancet"},{"key":"7808_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/nejmoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/nejmoa1708322","journal-title":"N Engl J Med"},{"key":"7808_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/mr\/roac059","volume":"33","author":"T Mochizuki","year":"2023","unstructured":"Mochizuki T, Yano K, Ikari K et al (2023) Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: a randomized clinical pilot study. Mod Rheumatol 33:490\u2013495. https:\/\/doi.org\/10.1093\/mr\/roac059","journal-title":"Mod Rheumatol"},{"key":"7808_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081660","volume":"10","author":"A Vestergaard Kvist","year":"2021","unstructured":"Vestergaard Kvist A, Faruque J, Vallejo-Yag\u00fce E et al (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system (FAERS). J Clin Med 10:1660. https:\/\/doi.org\/10.3390\/jcm10081660","journal-title":"J Clin Med"},{"key":"7808_CR9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae173","author":"J Stokar","year":"2024","unstructured":"Stokar J, Szalat A (2024) Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae173","journal-title":"J Clin Endocrinol Metab"},{"key":"7808_CR10","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"key":"7808_CR11","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","volume":"27","author":"R Lindsay","year":"2016","unstructured":"Lindsay R, Krege JH, Marin F et al (2016) Teriparatide for osteoporosis: importance of the full course. Osteoporos Int 27:2395\u20132410. https:\/\/doi.org\/10.1007\/s00198-016-3534-6","journal-title":"Osteoporos Int"},{"key":"7808_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep 14:101068. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"key":"7808_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10637","author":"H Inose","year":"2022","unstructured":"Inose H, Ariga A, Motoyoshi T et al (2022) The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10637","journal-title":"JBMR Plus"},{"key":"7808_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","volume":"3","author":"Z Bursac","year":"2008","unstructured":"Bursac Z, Gauss CH, Williams DK et al (2008) Purposeful selection of variables in logistic regression. Source Code Biol Med 3:17. https:\/\/doi.org\/10.1186\/1751-0473-3-17","journal-title":"Source Code Biol Med"},{"key":"7808_CR15","unstructured":"The Royal Australian College of General Practitioners HBA (2024) Osteoporosis prevention, diagnosis and management post-menopausal women and men over 50 years of age, 3rd edn. https:\/\/www.racgp.org.au\/clinical-resources\/clinical-guidelines\/key-racgp-guidelines\/view-all-racgp-guidelines\/osteoporosis\/executive-summary. Accessed\u00a010 Jun 2024"},{"key":"7808_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/nejmoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/nejmoa1305224","journal-title":"N Engl J Med"},{"key":"7808_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91248-6","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M et al (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-91248-6","journal-title":"Sci Rep"},{"key":"7808_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP et al (2007) Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326\u2013339. https:\/\/doi.org\/10.7326\/0003-4819-146-5-200703060-00005","journal-title":"Ann Intern Med"},{"key":"7808_CR19","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","volume":"101","author":"JN Tsai","year":"2016","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SM et al (2016) Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab 101:2023\u20132030. https:\/\/doi.org\/10.1210\/jc.2016-1160","journal-title":"J Clin Endocrinol Metab"},{"key":"7808_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf119","volume":"9","author":"T Damm","year":"2025","unstructured":"Damm T, Libanati C, Pena J et al (2025) Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density. JBMR Plus 9:ziaf119. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf119","journal-title":"JBMR Plus"},{"key":"7808_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2214\/ajr.167.1.8659357","volume":"167","author":"S Grampp","year":"1996","unstructured":"Grampp S, Jergas M, Lang P et al (1996) Quantitative CT assessment of the lumbar spine and radius in patients with osteoporosis. AJR Am J Roentgenol 167:133\u2013140. https:\/\/doi.org\/10.2214\/ajr.167.1.8659357","journal-title":"AJR Am J Roentgenol"},{"key":"7808_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteoporos Int"},{"key":"7808_CR23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","volume":"33","author":"A Tominaga","year":"2022","unstructured":"Tominaga A, Wada K, Okazaki K et al (2022) Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporos Int 33:1265\u20131273. https:\/\/doi.org\/10.1007\/s00198-021-06261-2","journal-title":"Osteoporos Int"},{"key":"7808_CR24","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi M-L et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483\u20134492. https:\/\/doi.org\/10.1210\/jc.2013-1597","journal-title":"J Clin Endocrinol Metab"},{"key":"7808_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"7808_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP et al (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152. https:\/\/doi.org\/10.3390\/jcm10010152","journal-title":"J Clin Med"},{"key":"7808_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2025.101847","volume":"25","author":"S Kumar","year":"2025","unstructured":"Kumar S, Streeter C, McDonald MM et al (2025) Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomes. Bone Rep 25:101847. https:\/\/doi.org\/10.1016\/j.bonr.2025.101847","journal-title":"Bone Rep"},{"key":"7808_CR28","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H et al (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:1807\u20131813. https:\/\/doi.org\/10.1007\/s00198-022-06386-y","journal-title":"Osteoporos Int"},{"key":"7808_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07139-9","author":"S Kumar","year":"2024","unstructured":"Kumar S, Gild ML, McDonald MM et al (2024) A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-024-07139-9","journal-title":"Osteoporos Int"},{"key":"7808_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"7808_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","author":"G Adami","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M et al (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae016","journal-title":"JBMR Plus"},{"key":"7808_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-020-01103-2","author":"P Naik-Panvelkar","year":"2020","unstructured":"Naik-Panvelkar P, Norman S, Elgebaly Z et al (2020) Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice. BMC Fam Pract. https:\/\/doi.org\/10.1186\/s12875-020-01103-2","journal-title":"BMC Fam Pract"},{"key":"7808_CR33","doi-asserted-by":"publisher","unstructured":"Hartz MC, Johannessen FB, Harslof T et al (2024) The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae484","DOI":"10.1210\/clinem\/dgae484"},{"key":"7808_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/17455057221125577","volume":"18","author":"SY Lim","year":"2022","unstructured":"Lim SY (2022) Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk. Womens Health 18:174550572211255. https:\/\/doi.org\/10.1177\/17455057221125577","journal-title":"Womens Health"},{"key":"7808_CR35","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/art.42538","volume":"75","author":"J Zheng","year":"2023","unstructured":"Zheng J, Wheeler E, Pietzner M et al (2023) Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization. Arthritis Rheumatol 75:1781\u20131792. https:\/\/doi.org\/10.1002\/art.42538","journal-title":"Arthritis Rheumatol"},{"key":"7808_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/8755122520967632","volume":"37","author":"SA Miller","year":"2021","unstructured":"Miller SA, St. Onge EL, Whalen KL (2021) Romosozumab: a novel agent in the treatment for postmenopausal osteoporosis. J Pharm Technol 37:45\u201352. https:\/\/doi.org\/10.1177\/8755122520967632","journal-title":"J Pharm Technol"},{"key":"7808_CR37","doi-asserted-by":"publisher","unstructured":"Maloney NJ, Ravi V, Cheng K et al (2020) Stevens\u2010Johnson syndrome and toxic epidermal necrolysis\u2010like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 59. https:\/\/doi.org\/10.1111\/ijd.14811","DOI":"10.1111\/ijd.14811"},{"key":"7808_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s2213-8587(24)00092-5","volume":"12","author":"DM Black","year":"2024","unstructured":"Black DM, Thompson AR, Eastell R et al (2024) Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE. Lancet Diabetes Endocrinol 12:371\u2013373. https:\/\/doi.org\/10.1016\/s2213-8587(24)00092-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7808_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10546","author":"F Cosman","year":"2021","unstructured":"Cosman F, Libanati C, Deignan C et al (2021) Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10546","journal-title":"JBMR Plus"},{"key":"7808_CR40","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/s2213-8587(24)00225-0","volume":"12","author":"IR Reid","year":"2024","unstructured":"Reid IR, McClung MR (2024) Osteopenia: a key target for fracture prevention. Lancet Diabetes Endocrinol 12:856\u2013864. https:\/\/doi.org\/10.1016\/s2213-8587(24)00225-0","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07808-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:26:57Z","timestamp":1779290817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07808-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7808"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07808-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}